Press Releases<< Back
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
The poster discussions will include:
- Results from a study performed using tissue samples from a patient database from
Kaiser Permanente's Northern Californiaregion that examine GPS performance in predicting biochemical recurrence, prostate cancer-specific death and metastasis in patients with clinically low-, intermediate- and high-risk prostate cancer who were treated with radical prostatectomy;
- Results of a prospective, multi-site study that evaluated GPS as a predictor of adverse pathology in men treated with radical prostatectomy for clinically low-risk prostate cancer;
- Interim results examining clinical utility from a study evaluating GPS impact on rates of active surveillance utilization and persistence; and
- Results from a study conducted at six
Veterans Affairsmedical centers that compared treatment patterns before and after introduction of GPS to determine if the test improves risk stratification and the use of active surveillance.
Complete results of the studies will be presented as follows (all times are in Eastern Daylight Time) and abstracts are now available at http://www.aua2017.org/abstracts/.
- Abstract: MP20-05
Moderated Poster: "A diagnostic biopsy-based Genomic Prostate Score as an independent predictor of prostate cancer death and metastasis in men with localized prostate cancer"
Van Den Eeden S, Zhang N, Shan J, Quesenberry C, Han J, Tsiatis A, Lu R, Lawrence J, Febbo P, Presti J.
BCEC Room 160
Time: 3:30 -
- Abstract: MP28-01
Moderated Poster: "A 17-gene panel for prediction of adverse pathology at radical prostatectomy: prospective validation"
Authors: Eggener S, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel A, Bennett J, Karsh L, Korman H, Febbo P, Denes B.
Time: 7 - 9 a.m.
- Abstract: MP28-11
Moderated Poster: "Impact of the 17-gene panel on active surveillance persistence in contemporary urologic practices: an interim analysis in an observational cohort"
Authors: Eure G, Germany R, Given R, Glowacki R, Richardson T, Goldfischer E, Lu R, Shindel A,
Bennett J. Febbo P, Denes B.
Time: 7 - 9 a.m.
- Abstract: MP86-16
Moderated Poster: "A multi-center analysis of prostate cancer (PCa) treatment among Veterans following introduction of the 17-gene Genomic Prostate Score (GPS) assay"
Authors: Dash A, Lynch J, Rothney M, Salup R, Ercole C, Mathur S, Duchene D, Basler J, Hernandez J, Liss M, Porter M, Wright JL.
BCEC Room 156
Time: 3:30 -
About the Oncotype DX® Genomic Prostate Score™
About Genomic Health
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the applicability of clinical study results to actual outcomes; the impact of results from clinical studies on market adoption of Oncotype DX tests, our ability to develop and commercialize new tests and expand into new markets domestically and internationally; unanticipated costs or delays in research and development efforts; and other risks and uncertainties set forth in our filings with the
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomic-health-announces-upcoming-presentation-of-four-oncotype-dx-studies-including-new-validation-on-its-ability-to-predict-prostate-cancer-specific-death-and-metastases-300451224.html
News Provided by Acquire Media